Company / Revenue
Acadia Pharmaceuticals Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.1B
FY2025
5-year range
$484.1M / $1.1B
FY2021-FY2025
Trend
+11.9%
vs FY2024
Sector context
#40 of 155
Health Care
What the data says
At $1.1B, Acadia Pharmaceuticals's revenue ranks #40 of 155 in the Health Care sector. Revenue has increased for 9 consecutive years, from $17M in FY2016 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +19.4%.
Improved from $726M to $1.1B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +27.5%
- 5-Year CAGR
- +19.4%
- 10-Year CAGR
- -
Sector benchmark
#40 of 155 in Health CareTop 26% of 155This company $1.1B Sector average $4.5B
▼
-76.0% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's revenue has grown for 9 consecutive years.
- 5-year CAGR of +19.4%, indicating consistent growth.
- In FY2025, revenue increased 11.9% year-over-year.
- Ranks #40 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +11.9% |
| FY2024 | $957.8M | +31.8% |
| FY2023 | $726.4M | +40.4% |
| FY2022 | $517.2M | +6.8% |
| FY2021 | $484.1M | +9.6% |
| FY2020 | $441.8M | +30.3% |
| FY2019 | $339.1M | +51.5% |
| FY2018 | $223.8M | +79.2% |
| FY2017 | $124.9M | +620.7% |
| FY2016 | $17.3M | +28311.5% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026